Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04677153

Rapid HCV Treatment Access for Persons Who Use Drugs — RAPID-HCV  

Hepatitis C Virus Infection, Response to Therapy of Clinical Trial

Official title:
Rapid HCV Test and Treat to Increase HCV Treatment Uptake Among People Who Use Drugs

Clinical Trial Summary

This study is being done to compare two strategies to deliver HCV treatment to persons with hepatitis C virus (HCV) who also use drugs and are participating in an outpatient opioid treatment program (OTP). Participants will be randomized into one of two treatment groups: 1. Test and treat plus peer-mentors: This treatment group will be offered 8 weeks of glecaprevir/pibrentasvir (an FDA approved HCV treatment) within days of HCV diagnosis at the OTP. Participants in this group will receive treatment adherence support from a peer-mentor who is someone who has been cured of HCV infection. 2. Standard of care HCV treatment referral: This treatment group will be referred to an offsite HCV treatment location. This is the usual care for anyone who tests positive for HCV at the OTP who is not participating in this study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Hepatitis C
  • Hepatitis C Virus Infection, Response to Therapy of
Clinical Trial Details
NCT number NCT04677153
Study type Interventional
Source Johns Hopkins University
Contact Oluwaseun Falade-Nwulia, MBBS, MPH
Phone 4422871964
Email ofalade1@jhmi.edu
Status Recruiting
Phase N/A
Start date August 6, 2021
Completion date January 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04596475 - Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor Phase 1/Phase 2
Recruiting NCT05361603 - Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures
Recruiting NCT05376943 - Possible Differences in HCC Course Depending on DAA Treatment
Recruiting NCT04251572 - HCV Reinfection After DAA Therapy in PWID in Belgium N/A
Completed NCT03369327 - Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus Phase 3
Recruiting NCT04768517 - HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
Recruiting NCT04732832 - HCV Reinfection in HD Patients Achieving SVR
Recruiting NCT01572233 - Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection N/A
Withdrawn NCT03381859 - Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Phase 4
Completed NCT03453346 - Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C N/A
Completed NCT02402218 - CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS N/A
Completed NCT01473056 - Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects Phase 1
Completed NCT03250910 - Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients Phase 4
Enrolling by invitation NCT03343444 - Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents Phase 3